Answers are grounded in this paper and cite their sources.
Background The association between proton pump inhibitor (PPI) use and inflammatory bowel disease (IBD) remains uncertain. We evaluated PPI-associated IBD reporting signals and explored pantoprazole-related molecular and epithelial inflammatory responses. Methods FAERS reports from 2004 to 2024 were analyzed by disproportionality analysis. IBD transcriptomic datasets were integrated with predicted pantoprazole targets, followed by pathway analysis and machine-learning-based gene prioritization. Cell-type distribution was examined in GSE214695. Molecular docking and molecular dynamics simulation were performed to examine the predicted pantoprazole–LCN2 complex. HT29 and NCM460 cells were used for CCK-8 and RT-qPCR validation. For inflammatory challenge, HT29 cells were pretreated with pantoprazole and then exposed to TNF-α. Results Among 148,426 PPI-associated reports, 1,402 involved IBD-related events. Pantoprazole showed the strongest reporting signal (ROR 5.64, 95% CI 5.31–6.00). A total of 109 overlapping candidate genes were identified, and six were prioritized: BACE2, S100A9, SORD, MMP3, LCN2, and SELP. Pantoprazole increased LCN2 mRNA expression in both HT29 and NCM460 cells, and further increased TNF-α-induced IL6 and IL8 mRNA expression in HT29 cells. Conclusion Pantoprazole showed a disproportionate IBD reporting signal in FAERS and altered epithelial inflammatory responsiveness in vitro . These findings do not establish causality and require further epidemiological and mechanistic validation.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: